Event info
Date:24 Aug
Time:15.00 - 16.30
Venue:Online
Contact person
Sofia Norås

Sofia Norås

Project Manager

sn@mva.org

+45 2337 0040

MVA Oncology Network Meeting – Development of Orphan Drugs Within Oncology

Medicon Valley Alliance together with member company Ascelia Pharma have the pleasure to invite you to the 11th meeting of the Medicon Valley Alliance Oncology Network on the 24th of August, 2021.

Rare disease affects a small number of patients; the European Medicines Agency defines rare disease where the prevalence of the disease is less than 5 in 10,000 persons and the US Food & Drug Administration defines it as less than 200.000 persons in the US. However there are around 7,000 identified rare diseases and they are affecting over 300 million people globally. Regulatory authorities are encouraging development of drugs for rare diseases, called orphan drugs, and offer incentives for the Life science industry to develop orphan drugs. In recent years the number of orphan drugs in development has increased and the trend is also true within Oncology which today is one of the main therapeutic areas with orphan designations.

In this MVA Oncology network webinar Ascelia Pharma will share knowledge on how they are building an international biotech company focusing on Orphan Oncology. We will also hear from leading regulatory experts from NDA Advisory Board and get insights from TFS HealthScience on patient recruitment and patient identification in orphan oncology.

Due to the current Covid-19 situation in Denmark and Sweden this meeting is delivered in a shorter webinar format instead of a regular networking meeting.

Date: 24th of August, 2021
Time: 15.00 – 16.30
Venue: Online
Host and Moderator: Ascelia Pharma

Link to the recording of the meeting HERE


PROGRAM

14.50 – 15.00Online platform open for connecting participants
15.00 – 15.05Welcome and introduction
Petter Hartman, CEO, Medicon Valley Alliance
Andreas Norlin, PhD, Project Director and Head of Nonclinical Development, Ascelia Pharma
15.05 – 15.10Challenges with IP in Orphan drugs
Jens Viktor Nørgaard, Partner, Head of Biotechnology & Plant Sciences, European Patent Attorney, Høiberg
15.10 – 15.30
Building an Orphan Oncology company: past experience and future perspectives
Andreas Norlin, PhD, Project Director and Head of Nonclinical Development, Ascelia Pharma
15.30 – 15.50Regulatory challenges in small populations
Steffen Thirstrup, Director, NDA Advisory Board

15.50 – 16.10

Patient identification and recruitment strategies in orphan oncology 
Alison Sampson, Head of Pediatrics, Rare Diseases, Orphan Prod. EU, TFS HealthScience
Peter Larson, VP Clinical Services Oncology, TFS HealthScience
16.10 – 16.30Discussion and Q&A

Deadline for registration is 23rd of August, 2021.

 

For more information please contact Sofia Norås sn@mva.org

The network
MVA Oncology Network is a professional and social network for professors, PIs and corporate level executives from the regional oncology eco-system. The network focuses on best practice, experience and current challenges for public-private collaboration and the commercialization of oncology related R&D in the Medicon Valley region.

Joining the network is free of charge and is limited to Medicon Valley Alliance members only. However, non-member organizations and companies are welcome to attend one network event to evaluate if joining the network is relevant. If so, becoming a member of Medicon Valley Alliance will automatically allow you to join the oncology network.

HostSponsor of the event

 

 

MVA Oncology Network is managed by 

In collaboration with 

Lunduniversity logo